No description
-
2015 (v1)PublicationUploaded on: April 14, 2023
-
2011 (v1)Publication
No description
Uploaded on: April 14, 2023 -
2011 (v1)Publication
No description
Uploaded on: April 14, 2023 -
2012 (v1)Publication
No description
Uploaded on: April 14, 2023 -
2013 (v1)Publication
Approximately 6% of women with breast cancer are diagnosed before the age of 40. Young age is an independent predictor of adverse outcome and most young breast cancer patients receive systemic treatment with chemotherapy, hormonal therapy or both. The loss or impairment of fertility is a potential side effect of antineoplastic treatments. Due...
Uploaded on: April 14, 2023 -
2011 (v1)Publication
No description
Uploaded on: April 14, 2023 -
2012 (v1)Publication
No description
Uploaded on: April 14, 2023 -
2016 (v1)Publication
Introduction: Endocrine therapy is considered the cornerstone treatment for postmenopausal women with hormone-receptor positive metastatic breast cancer. Fulvestrant is a selective estrogen receptor down-regulator (SERD) with demonstrated activity and efficacy in the treatment of these patients.Areas covered: The present manuscript aims to...
Uploaded on: April 14, 2023 -
2010 (v1)Publication
No description
Uploaded on: April 14, 2023 -
2010 (v1)Publication
No description
Uploaded on: April 14, 2023 -
2014 (v1)Publication
No description
Uploaded on: April 14, 2023 -
2011 (v1)Publication
No description
Uploaded on: April 14, 2023 -
2013 (v1)Publication
Background: Neoadjuvant anthracycline- and taxane-based chemotherapy is frequently administered in breast cancer. Pathological complete response (pCR) rates vary according to clinical disease stage and biology of breast cancer. The critical role of angiogenesis in the progression of breast cancer, together with significantly improved efficacy...
Uploaded on: April 14, 2023 -
2014 (v1)Publication
Background: The role of temporary ovarian suppression with gonadotropin-releasing hormone analogues (GnRHa) in the prevention of chemotherapy-induced premature ovarian failure (POP) is still controversial. We conducted a systematic review and meta-analysis of randomized trials evaluating the efficacy of GnRHa, given before and during...
Uploaded on: April 14, 2023 -
2015 (v1)Publication
Background: Trastuzumab is a humanized monoclonal antibody (mAb) currently used for the treatment of breast cancer (BC) patients with HER-2 overexpressing tumor subtype. Previous data reported the involvement of Fc gamma RIIIA/IIA gene polymorphisms and/or antibody-dependent cellular cytotoxicity (ADCC) in the therapeutic efficacy of...
Uploaded on: April 14, 2023